Division of Acute Care Surgery, LAC+USC Medical Center, Los Angeles, CA.
Division of Acute Care Surgical Services, VCU Medical Center, Richmond, VA.
Surgery. 2021 Feb;169(2):470-476. doi: 10.1016/j.surg.2020.07.040. Epub 2020 Sep 12.
Trauma care providers often face a dilemma regarding anticoagulation therapy initiation in patients with traumatic brain injury owing to the associated risks of traumatic brain injury progression. The aims of this study were the following: (1) to describe the current practice of anticoagulation therapy in traumatic brain injury patients and their outcomes and (2) to identify factors associated with the progression of traumatic brain injury after anticoagulation therapy.
In this multicenter prospective observational study, we included computed tomography-proven traumatic brain injury patients who received anticoagulation therapy within 30 days of hospital admission. Our primary outcome was the incidence of clinically significant progression of traumatic brain injury after anticoagulation therapy initiation.
A total of 168 patients were enrolled more than 22 months. Atrial fibrillation and venous thromboembolism were the most common pre-injury and postinjury anticoagulation therapy indications, respectively. Overall, 16 patients (9.6%) experienced clinically significant traumatic brain injury progression after anticoagulation therapy, out of which 9 (5.4%) patients subsequently required neurosurgical interventions. Between patients with clinical progression of traumatic brain injury and patients who showed no such progression, there were no significant differences in the baseline demographics and severity of traumatic brain injury. However, anticoagulation therapy was initiated significantly earlier in patients of the deterioration group than those of the no-deterioration group (4.5 days vs 11 days, P = .015). In a multiple logistic regression model, patients who received anticoagulation therapy later after injury had significantly lower risk of clinically significant traumatic brain injury progression (odds ratio: 0.915 for each day, 95% confidence interval: 0.841-0.995, P = .037).
Our results suggest that early anticoagulation therapy is associated with higher risk of traumatic brain injury progression, thus a balance between bleeding and thromboembolic risks should be carefully evaluated in each case before initiating anticoagulation therapy.
由于创伤性脑损伤进展的相关风险,创伤护理提供者在创伤性脑损伤患者中经常面临抗凝治疗启动的困境。本研究的目的如下:(1)描述创伤性脑损伤患者抗凝治疗的现状及其结局,(2)确定抗凝治疗后创伤性脑损伤进展的相关因素。
在这项多中心前瞻性观察性研究中,我们纳入了在入院后 30 天内接受抗凝治疗的计算机断层扫描(CT)证实的创伤性脑损伤患者。我们的主要结局是抗凝治疗开始后创伤性脑损伤临床显著进展的发生率。
共纳入 168 例患者,超过 22 个月。房颤和静脉血栓栓塞症分别是最常见的创伤前和创伤后抗凝治疗指征。总体而言,16 名患者(9.6%)在抗凝治疗后出现临床显著的创伤性脑损伤进展,其中 9 名(5.4%)患者随后需要神经外科干预。在有临床进展性创伤性脑损伤的患者和没有这种进展的患者之间,基线人口统计学特征和创伤性脑损伤严重程度没有显著差异。然而,在病情恶化组患者中,抗凝治疗开始的时间明显早于无恶化组患者(4.5 天比 11 天,P =.015)。在多因素逻辑回归模型中,受伤后接受抗凝治疗时间较晚的患者,其发生临床显著创伤性脑损伤进展的风险显著降低(每延迟一天的比值比为 0.915,95%置信区间:0.841-0.995,P =.037)。
我们的研究结果表明,早期抗凝治疗与创伤性脑损伤进展的风险增加相关,因此在开始抗凝治疗之前,应仔细评估每个病例的出血和血栓栓塞风险之间的平衡。